Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies

Diana Crivellari, Enzo Galligioni, Sergio Frustaci, Giampietro Gasparini, Emanuela Vaccher, Giovanni Lo Re, Renato Talamini, Silvio Monfardini, Giovanni Ambroso

Research output: Contribution to journalArticlepeer-review

Abstract

In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day. Previous treatment consisted of additive hormones in 29 patients, oophorectomy in 8, and chemotherapy in 32. Among the 37 patients evaluablefor response and toxicity, 5 objective responses (16.2% and 20 stable diseases (54% were noted. Toxicity, absent in 23 patients (62.I % and mild in 14, consisted mainly of Grade I (WHO) nausea, drowsiness, cutaneous rash, and dizziness. Responders and patients with stable disease experienced a similar survival (median not reached at 22 months). Aminoglutethimide at low doses appears to be beneficial in patients refractory to conventional therapies even if the objective response rate is low.

Original languageEnglish
Pages (from-to)113-116
Number of pages4
JournalCancer Investigation
Volume7
Issue number2
DOIs
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies'. Together they form a unique fingerprint.

Cite this